Sort
10,766 grants matching “checkpoint inhibitor”
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host
$849,297Ronald Levy · Stanford University · R35 · FY2021 · CA
Signal Transduction Events and the Regulation of Cell Growth
$848,376Jane Neckers · Division Of Clinical Sciences - Nci · ZIC · FY2017 · CA
Rapid highly multi-plexed immuno-profiling of solid tumors by SpectralEdge imaging
$847,774Eric Kaldjian · Rarecyte, Inc. · R44 · FY2021 · CA
Therapeutic Dendritic Cell Vaccine for HIV
$847,500Nathaniel R. Landau · New York University School Of Medicine · DP1 · FY2020 · DA
Therapeutic Dendritic Cell Vaccine for HIV
$847,500Nathaniel R. Landau · New York University School Of Medicine · DP1 · FY2019 · DA
Therapeutic Dendritic Cell Vaccine for HIV
$847,500Nathaniel R. Landau · New York University School Of Medicine · DP1 · FY2018 · DA
Therapeutic Dendritic Cell Vaccine for HIV
$847,500Nathaniel R. Landau · New York University School Of Medicine · DP1 · FY2021 · DA
Therapeutic Dendritic Cell Vaccine for HIV
$847,500Nathaniel R. Landau · New York University School Of Medicine · DP1 · FY2023 · DA
Gene Expression At The Beginning Of Mammalian Development
$847,492Melvin Depamphilis · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2011 · HD
Initiation Of DNA Replication In Mammalian Chromosomes
$847,492Melvin Depamphilis · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2011 · HD
Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy
$846,982Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R35 · FY2025 · CA
Signal Transduction Events and the Regulation of Cell Growth
$846,744Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2015 · CA
Novel Approach to High-Throughput Identification and Characterization of Neoantigen-Specific T-Cell Receptors to Guide Immunotherapy Development.
$846,678Magali Soumillon · Flexomics Llc · R44 · FY2023 · CA
Clinical trials employing cancer vaccine combination therapies
$846,484James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$846,484James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$845,601Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2023 · CA
Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
$845,062Darell D Bigner · Duke University · R35 · FY2020 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
$845,000Eliezer M Van Allen · Dana-Farber Cancer Inst · U01 · FY2021 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
$844,999Eliezer M Van Allen · Dana-Farber Cancer Inst · U01 · FY2022 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
$844,999Eliezer M Van Allen · Dana-Farber Cancer Inst · U01 · FY2020 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
$842,916Eliezer M Van Allen · Dana-Farber Cancer Inst · U01 · FY2019 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
$841,459Eliezer M Van Allen · Dana-Farber Cancer Inst · U01 · FY2018 · CA
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection
$839,997Harris Goldstein · Albert Einstein College Of Medicine · R01 · FY2023 · AI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection
$839,997Harris Goldstein · Albert Einstein College Of Medicine · R01 · FY2022 · AI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection
$839,997Harris Goldstein · Albert Einstein College Of Medicine · R01 · FY2024 · AI